25 analysts have shared their evaluations of Regeneron Pharmaceuticals REGN during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 17 | 4 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 1 | 0 |
| 2M Ago | 1 | 13 | 2 | 0 | 0 |
| 3M Ago | 2 | 4 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $1086.64, a high estimate of $1300.00, and a low estimate of $165.00. A 10.22% drop is evident in the current average compared to the previous average price target of $1210.38.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of Regeneron Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| John Newman | Canaccord Genuity | Announces | Hold | $165.00 | - |
| Tim Anderson | B of A Securities | Announces | Underperform | $565.00 | - |
| Alexandria Hammond | Wolfe Research | Announces | Outperform | $1150.00 | - |
| Geoff Meacham | Citigroup | Announces | Neutral | $895.00 | - |
| Hartaj Singh | Oppenheimer | Lowers | Outperform | $1000.00 | $1150.00 |
| Matthew Harrison | Morgan Stanley | Lowers | Overweight | $1184.00 | $1235.00 |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $1215.00 | $1260.00 |
| Carter Gould | Barclays | Lowers | Overweight | $1065.00 | $1080.00 |
| Christopher Raymond | Piper Sandler | Lowers | Overweight | $1195.00 | $1242.00 |
| Evan David Seigerman | BMO Capital | Lowers | Outperform | $1190.00 | $1300.00 |
| Srikripa Devarakonda | Truist Securities | Lowers | Buy | $1126.00 | $1137.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1260.00 | $1260.00 |
| Cory Kasimov | Evercore ISI Group | Lowers | Outperform | $1175.00 | $1250.00 |
| Chris Schott | JP Morgan | Lowers | Overweight | $1150.00 | $1200.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $1015.00 | $1015.00 |
| Carter Gould | Barclays | Lowers | Overweight | $1080.00 | $1220.00 |
| Mohit Bansal | Wells Fargo | Lowers | Overweight | $1050.00 | $1200.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1260.00 | $1260.00 |
| Srikripa Devarakonda | Truist Securities | Lowers | Buy | $1137.00 | $1200.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1260.00 | $1252.00 |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $1252.00 | $1282.00 |
| Evan David Seigerman | BMO Capital | Maintains | Outperform | $1300.00 | $1300.00 |
| Srikripa Devarakonda | Truist Securities | Maintains | Buy | $1200.00 | $1200.00 |
| David Risinger | Leerink Partners | Lowers | Market Perform | $1077.00 | $1175.00 |
| Mohit Bansal | Wells Fargo | Maintains | Overweight | $1200.00 | $1200.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regeneron Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Regeneron Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regeneron Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Financial Milestones: Regeneron Pharmaceuticals's Journey
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Regeneron Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.65% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 36.03% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 4.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 3.65%. This signifies efficient management of assets and strong financial health.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
